Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Overview of attention for article published in Respiratory Research, February 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#31 of 3,063)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 14 news stories from 14 outlets.

New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy TITUSVILLE, N.J.…

TITUSVILLE, N.J., July 30, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson

TITUSVILLE, N.J., July 30, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson

New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy TITUSVILLE, N.J.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 10 additional news stories.